Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Designed to make life easier with hassle-free refills, you can decide which program fits your lifestyle
As more research emerges, we continue to refine our approaches to managing side effects and improving patient outcomes
CONTAINS DESICCANT PACKET FOR FRESHNESS
Address high cost pharmacy spend Deliver transformative outcomes to the 40% of members with diabetes on high cost drugs
The overall response rate (ORR) for CM patients to ipilimumab, nivolumab, pembrolizumab and atezolizumab is 12%, 40%, 33% and 30% respectively (167169), while the combined treatment of ipilimumab with nivolumab significantly improves the ORR to 61% with median progression-free survival (PFS) of 11.5 months (170, 171)
US$ 27.68
US$ 22.08
US$ 25.94
US$ 25.52
US$ 28.21
US$ 22.38
US$ 23.83
US$ 28.76
US$ 21.25
US$ 25.70
